Odds ratio and 95% confidence interval (CI) per lipoprotein-associated phospholipase A 2 -lowering F variant, adjusted for sex, region, age, and relatedness. Bonferroni-corrected p values are based on 1 (primary) and 7 (secondary) endpoint tests.
phatidylcholine and oxidized free fatty acids through hydrolysis of oxidized phospholipids carried on lowdensity lipoproteins in atherosclerotic plaques.
Although increased Lp-PLA 2 activity has been associated with higher risks of occlusive vascular diseases, recent phase III trials of the Lp-PLA 2 inhibitor darapladib, which reduces Lp-PLA 2 activity by w60%, failed to establish a protective role of darapladib for prevention of major vascular events in patients with stable coronary heart disease (CHD) or acute coronary syndrome (1, 2) .
A V279F loss-of-function variant in the PLA2G7 gene encoding Lp-PLA 2 , resulting in 50% lower activity for each copy of the variant, is common in East Asians (3) and allows an unbiased assessment of the causal effects of lifelong lower Lp-PLA 2 activity, analogous to randomized trials of Lp-PLA 2 inhibition (4). We power to detect a 20% lower relative risk at p < 0.01.
As a context, the trials were powered to detect 15% risk reductions, and differences in lifelong exposure associated with genetic variants would be expected to have greater effects than intervening for a few years in later life (4). Secondary endpoints, for which power was lower, included major coronary events (CHD death, myocardial infarction), major occlusive events (CHD death, myocardial infarction, ischemic stroke), and stroke subtypes.
The mean baseline age of participants was 51 years and 40% were men. History of CHD was reported by 3%, stroke or transient ischemic attack by 2%, diabetes by 6%, and hypertension by 12% of participants.
Antihypertensive or statin use was reported by 5% and 0.2% of participants, respectively. The frequency of PLA2G7 V279F was 5% overall, but varied from 3% to 7% by region (p heterogeneity <0.0001) and 10.6% of participants (n ¼ 9,691) had at least 1 loss-of-function variant. There were no differences in blood pressure, adiposity, or other baseline characteristics by genotype. There was no significant association of PLA2G7 
